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Abstract (word count = 250) 
 
Accurate diagnosis of plasmacytoid urothelial carcinoma (PUC) is important given its poor 
prognosis and frequent presentation at high stage. We aim to assess the clinicopathologic 
features, molecular aberrations, and follow-up data in a series of PUC cases from a single tertiary 
cancer center. Seventy-two urinary bladder, ureteral, and renal pelvic specimens with urothelial 
carcinoma with plasmacytoid differentiation were identified. Immunohistochemical (IHC) stains 
were performed on 48 cases. Among urinary bladder origin markers, GATA3 was most sensitive 
(96%). Breast carcinoma markers (ER, mammaglobin) were usually negative, but PR stained 1 
case (4%). Neuroendocrine markers CD56 and TTF-1 were each positive in 1 case (4% and 4%, 
respectively). Gastrointestinal adenocarcinoma marker CDX2 was positive in 4 cases (15%), but 
nuclear β-catenin was negative in all cases. CD138 was positive in 83% and e-cadherin 
expression was lost in 57% of cases.  Fluorescence in situ hybridization (FISH) using the 
UroVysion Bladder Cancer Kit and FGFR3 mutational analysis using polymerase chain reaction 
(PCR) were performed on 15 cases; deletion of chromosome 9p21 was common (60%) and 
FGFR3 mutations were detected in 60% of cases (5 cases had both deletion 9p21 and FGFR3 
mutations). Cases were divided into 3 morphologic groups: classic (29%), desmoplastic (35%), 
and pleomorphic (36%). The three morphologic subtypes had distinct survival outcomes 
(p=0.083), with median survival for all patients 18 being months versus 10 months for the 
desmoplastic group.  
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1. Introduction 
 
Urothelial carcinoma accounts for approximately 90% of primary urinary bladder carcinomas 
and has a tremendous propensity for morphologic variations [1]. Accurate identification of 
variants is important for a variety of reasons, as some variants have prognostic significance and 
others may be mistaken for a benign entity or another tumor [1]. In the most recent edition of the 
World Health Organization (WHO) Classification of Tumours of the Urinary System and Male 
Genital Organs, the plasmacytoid variant is combined with signet ring (lacking extracellular 
mucin) and diffuse variants [1]. The plasmacytoid variant in particular has been associated with 
presentation at a higher pathologic T stage, a higher rate of positive surgical margins, and lower 
overall survival [2]. Awareness of this variant is crucial when interpreting ureteral and urethral 
margins on frozen section, given its propensity to infiltrate the soft tissue surrounding the 
urothelium rather than involving the overlying urothelium itself [3]. In addition, being alert to the 
unique pattern of discohesive, single cells that may infiltrate the sinusoids of lymph nodes is 
important in order to identify metastases [4]. 
 
One of the earliest references to primary signet ring cell carcinoma of the bladder in the literature 
is by Saphir in 1955, which describes cells with intracytoplasmic mucin that compressed the 
nuclei and gave them a crescent shape, cells with basophilic cytoplasm and eccentric nuclei, and 
cells resembling monocytes. He references another report of tumors composed almost 
exclusively of similar signet ring cells which were diffusely infiltrative and were associated with 
distant metastases [5]. In a subsequent study of signet ring cell carcinoma of the urinary bladder, 
Grignon et al. included linitis plastica-like growth in the definition and described similar cells to 
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those reported by Saphir [6]. Since that time, several case series have described the morphologic 
features of plasmacytoid urothelial carcinoma, the largest and most recent of which included 49 
cases from The University of Texas MD Anderson Cancer Center 
[7,8,9,10,11,12,13,14,15,16,17,18]. While these studies describe plasmacytoid differentiation as 
having a central or eccentric nucleus and infiltrative architecture consisting of discohesive, single 
cells and linear arrangements of cells, they rarely offer much additional detail [1]. Some authors 
mention a few other morphologic observations such as the presence of a stromal response in a 
minority of cases, however these additional descriptions are minimal and not a focal point of any 
particular study [12,13,19,20,21]. Some cases of urothelial carcinoma have been described as 
having rhabdoid differentiation, however the morphologic features and images in these studies 
fall within the spectrum of plasmacytoid differentiation outlined in most other papers 
[22,23,24,25]. Lastly, reports of conventional urothelial carcinoma with an infiltrative growth 
pattern as single cells or cords of cells often with associated desmoplasia have shown a 
particularly poor prognosis in those cases [26]. 
 
 
We aim to describe the detailed morphologic features, immunohistochemical expression pattern, 
molecular aberrations, and clinical follow-up of a large series of urothelial carcinoma with 
plasmacytoid/diffuse differentiation from a single institution. Previously reported 
immunohistochemical stain results have been reported by variety of authors. However, we 
provide a description of the staining pattern for pertinent stains when applied to a large series of 
tumors which were all processed by one laboratory, thus eliminating inter-laboratory technical 
issues as a possible explanation for aberrant staining. Likewise, we hope to expand upon 
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previously reported information regarding the link between molecular aberrations detected in 
conventional urothelial carcinoma and the plasmacytoid variant. 
 
2. Materials and methods 
 
A search of the pathology database at Indiana University (January 1996-September 2016) for in-
house specimens from the urinary bladder, renal pelvis, or ureter with a final diagnosis of 
urothelial carcinoma with plasmacytoid or signet ring cell differentiation was performed. 
Pathology reports were reviewed and data including patient demographics (age, sex), types of 
specimens, estimated quantity of plasmacytoid differentiation specified, pathologic AJCC TNM 
stage, and clinical follow-up data was collected. In addition, all available slides from each case 
were re-reviewed and the cases were divided into three different morphologic groups (please 
refer to the “Results” section to see criteria used for distinction). 
 
2.1 Immunohistochemistry 
 
A representative block from 48 cases of urothelial carcinoma with plasmacytoid differentiation 
was selected. Unstained slides were cut at 5 μm in thickness. The antibodies used are listed in 
Table 1. Immunohistochemical stains were performed as previously described [14]. Twenty-six 
cases were initially stained with all 16 antibodies. An additional 22 cases were selected because 
of unique morphologic features (classic morphology, pleomorphic cells, desmoplastic stromal 
reaction, etc.) and were stained with e-cadherin and CD138. Positivity was interpreted as nuclear 
for β-catenin, CDX2, estrogen receptor (ER), GATA3, p53, p63, progesterone receptor (PR), and 
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TTF-1. Positivity was cytoplasmic for 34βE12, keratin 7, keratin 20, and mammaglobin. 
Positivity was membranous for CD56, CD138, e-cadherin, thrombomodulin, and uroplakin III. 
Staining was scored for intensity (0: no staining; 1: weak; 2: moderate; 3: strong) and proportion 
of cells stained (0: 0%; 1: >0 to ≤25%; 2: >25 to ≤50%; 3: >50 to ≤75%; 4: >75 to 100%).  
 
2.2 UroVysion fluorescence in situ hybridization 
 
Unstained sections were prepared from available tissue blocks from 15 cases and were 
deparaffinized with xylene for fluorescence in situ hybridization using the UroVysion probe set. 
Slides were treated with absolute ethanol, then air-dried and boiled in a glass staining-jar with 1× 
citrate buffer (pH 6.0) (Zymed, CA) within a beaker filled with distilled water on a hot block for 
10 minutes. Slides were washed with distilled water and transferred to 2× sodium citrate buffer 
(SSC) for 5 minutes. The slides were air dried and digested with 0.75-mL pepsin (5 mg/mL in 
0.01 N HCl with 0.9% NaCl; Sigma, St Louis, MO) at 37°C for 40 minutes. The slides were then 
washed with distilled water and 2×SSC, followed by air-drying. Chromosome enumeration 
probes (CEP) for chromosomes 3, 7, and 17, and the locus specific indicator (LSI) probe for 
9p21 were labeled with fluorophores. CEP3, CEP7, and CEP17 probes were labeled with 
Spectrum Red, Spectrum Green, and Spectrum Aqua, respectively. LSI p16 (9p21) was labeled 
with Spectrum Gold (Vysis, Downers Grove, IL). The probes were diluted 1:10 with tDenHyb2 
(Insitus, Albuquerque, NM). Five microliters of diluted probes were added to each slide in 
reduced light conditions. The slides were then covered with a 22×22 cover slip, sealed with 
rubber cement and put into an opaque plastic box wrapped with aluminum foil. The slides were 
denatured at 83°C for 12 minutes and hybridized at 37°C overnight. After hybridization, the 
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slides were washed and counter-stained with 10 µL DAPI (Insitus, Albuquerque, NM) and sealed 
with a 50×22 cover slip. 
 
The stained slides were observed and documented using MetaSystem software (Belmont, MA) 
under 100× oil objective, using filters: SP-100 for DAPI, FITC MF-101 for Spectrum Green, 
Gold 31003 for Spectrum Gold, Aqua 31036V2 for Spectrum Aqua, and Texas Red Sp103 for 
Spectrum Red signals. Five sequential focus stacks with 0.4 µm intervals were acquired and 
integrated into a single image to reduce thickness-related artifacts. 
 
For each case, 200 nuclei were counted. Each cell was simultaneously analyzed for the signals of 
chromosomes 3, 7, and 17, and 9p21. Chromosomal gain or loss was defined based on the 
Gaussian model and relative to normal controls. The cut-off values were set at the mean+3 SD of 
the number of disomic cells in control individuals. The mean+3 SD represents a specificity of 
99.9%. Any tumor cases with a score beyond the cut-off value were considered to have either a 
gain or a loss of the designated chromosome(s). 
 
2.3 FGFR3 mutation analysis 
 
FGFR3 mutational analysis was performed on 15 cases. For the FGFR3 gene, exons 7, 10, and 
15 were amplified by polymerase chain reaction (PCR) using previously established primers. 
PCR was performed with 3ml of isolated genomic DNA in a final volume of 50 ml containing 
2.3 mM MgCl2, 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 2 mM deoxynucleotide triphosphates, 2 
mM each primer, and 2U Taq DNA polymerase (Bio-Rad, Hercules, CA, USA). Each PCR 
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protocol had an initial denaturing step of 95°C for 5 minutes, followed by 40 cycles of: 95°C for 
30 seconds, 55°C (for exons 7 and 15) or 58°C (for exon 10) for 30 seconds, and 72°C for 30 
seconds. There was a single final extension step at 72°C for 7 min. The PCR products were 
purified using the QIAquick PCR Purification kit (Qiagen Sciences, Germantown, MD, USA). 
DNA concentration of PCR products was measured and adjusted to 20 ng per microliter. 
Sequencing of the purified PCR product was then performed using an ABI Prism 3100 Genetic 
Analyzer (Applied Biosystems, Foster City, CA, USA). 
 
3. Results 
 
3.1 Epidemiology 
 
A total of 72 specimens from 69 patients were identified. Among the 69 patients, 56 were male 
and 13 female. The median patient age was 68 years (range: 36 to 91 years). Among the 72 
specimens, 5 were biopsies, 13 transurethral resections (TUR), 50 radical cystectomies (RC), 2 
nephroureterectomies (NU), and 2 were ureterectomies. Among the 50 radical cystectomy cases, 
there were 41 radical cystoprostatectomies in men, 8 radical cystectomies with pelvic 
exenteration in women, and 1 radical cystectomy with vaginal margins in a woman who was 
already status-post hysterectomy. Among the biopsy/TUR specimens, 7 patients went on to have 
a RC. Of those 7 RC cases, 3 had plasmacytoid morphology and were included in the series. 
Four cases were excluded from analysis because 2 had no residual disease, 1 had urothelial 
carcinoma in situ only (no plasmacytoid morphology), and slides from 1 case (from 1996) could 
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not be located for re-review and plasmacytoid/signet ring morphology was not mentioned in the 
pathology report.  
 
3.2 Gross findings 
 
Among resection cases, 83% (45/54) had a mass and 17% (9/54) had no mass present. Three 
cases (5%, 3/54) had a scar, all of which did not have a grossly identifiable mass. The presence 
or absence of a scar was not stated in the remaining 94% (51/54) of cases. Among cystectomies, 
34% (17/50) had a thickened bladder wall. Of note, the two ureterectomy specimens were 
described as having no gross abnormality. The two nephroureterectomies each had a mass 
described but no scar or thickening of the renal pelvis wall/proximal ureter was noted. 
 
3.3 Histopathology and morphologic groups 
 
After reviewing all of the cases three main morphologic groups were recognized. The first group 
was dubbed the “classic” group and were composed of cells somewhat resembling invasive 
lobular carcinoma of the breast. The cells had small to medium nuclei (generally two to three 
times larger than a lymphocyte), some of which were eccentrically located (plasmacytoid) and 
others were located in the center of the cell (monocytoid) (Fig. 1). Cells with signet ring-like 
morphology were also a feature of this group. Overall, the cells were singly scattered and 
discohesive or in loose aggregates forming linear cords. The second group was the 
“pleomorphic” group, in which cases were composed of cells with pleomorphic nuclei which 
were larger and had more atypia than the cells in the classic category (nuclei were generally at 
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least four times the size of a lymphocyte). A subset of these cases had markedly bizarre nuclear 
atypia which at times was rhabdoid in appearance (prominent nucleolus, eccentric eosinophilic 
cytoplasmic inclusion). This group was usually seen in association with more typical 
plasmacytoid cells. The third group of cases was were the “desmoplastic” group. Cells in this 
category were surrounded by an exuberant, desmoplastic stromal response. While a minority of 
the cells in the desmoplastic cases closely resembled the cells in the classic group, most of the 
cells were pleomorphic with more abundant cytoplasm. At times the cells in this third group 
more closely resembled conventional high grade urothelial carcinoma. 
 
Overall, 29% (21/72) of cases were in the classic category, 35% (25/72) in the exuberant 
desmoplasia category, and 36% (26/72) of cases were in the pleomorphic category. Among cases 
with an exuberant, desmoplastic stromal response, 84% (21/25) were composed of pleomorphic 
cells and 16% (4/25) were composed of cells with classic morphology. A total of 6 cases were 
noted to have marked/bizarre nuclear atypia, 3 of which were included in the category with 
exuberant desmoplasia and 3 of which were included in the pleomorphic category. Interestingly, 
a few of the cases in the classic category consisted of closely packed cells resembling a 
discohesive sheet, often located beneath the luminal surface of the urinary bladder. 
 
All cases were initially diagnosed as urothelial carcinoma with plasmacytoid (93%, 67/72) or 
signet ring (7%, 5/72) differentiation. The amount of plasmacytoid differentiation ranged from 
5% to 100% (median 25%). Additional variant differentiation was identified in 32% (23/72) of 
cases; additional variants included clear cell (4%, 1/23), giant cell (4%, 1/23), glandular (13%, 
3/23), micropapillary (13%, 3/23), nested (13%, 3/23), sarcomatoid (31%, 7/23), small cell (4%, 
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1/23), and squamous differentiation (18%, 4/23). Concomitant urothelial carcinoma in situ 
(UCIS) was present in 43% (31/72) of specimens.  
 
Overall, among resections the pathologic T category was most commonly pT4 (48%, 26/54), 
followed by pT3 (37%, 20/54), pT2 (13%, 7/54), and pT1 (2%, 1/54) (Table 2). In the classic 
category, 14% (3/21) of cases were pT1, 33% (7/21) pT2, 29% (6/31) pT3, and 24% (5/21) pT4. 
In the desmoplastic category, 0% (0/25) were pT1, 12% (3/25) pT2, 36% (9/25) pT3, and 52% 
(13/25) pT4. In the pleomorphic category, 11% (3/26) were pT1, 35% (9/26) pT2, 23% (6/26) 
pT3, and 31% (8/26) pT4. 
 
A positive ureteral margin was present in 9% (5/54) of all resection cases (3 invasive in soft 
tissue, 2 urothelial dysplasia). When analyzed by morphologic group, positive ureteral margins 
were present in 25% (4/16) of classic resection cases, 32% (7/22) of desmoplastic resection 
cases, and 19% (3/16) of pleomorphic resection cases; of these cases, 2 classic cases, 1 
desmoplastic case, and no pleomorphic cases were positive based on soft tissue invasion 
surrounding the ureteral lumen. The ureter was involved in 39% (21/54) of all resection cases (12 
invasive in soft tissue only, 1 invasive arising from the urothelium only, 5 UCIS only, 1 
urothelial dysplasia only, 1 invasive arising from the urothelium and in the soft tissue, and 1 
invasive in soft tissue and UCIS). A positive urethral margin was present in 4% (2/50) of radical 
cystectomies (1 invasive carcinoma, 1 UCIS). The urethra was involved in 10% (5/50) of radical 
cystectomies (2 invasive carcinoma, 1 invasive in soft tissue, 2 UCIS). 
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Among resection cases, 93% (50/54) included lymph nodes, 72% (36/50) of which had lymph 
node metastases. The majority of cases with positive lymph nodes were N2 (83%, 30/36), and a 
smaller number were N1 (14%, 5/36) and N3 (3%, 1/36). The median number of positive lymph 
nodes was 4 (range: 1-32), the median size of metastatic deposits was 1.3 cm (range: 0.1-3.9 
cm), and extranodal extension was present in 64% (23/36) of cases.  
 
Among radical cystoprostatectomies/cystectomies, 52% (26/50) had involvement of adjacent 
organs (Table 3). Among radical cystoprostatectomies, 37% (15/41) had involvement of the 
prostatic stroma and 37% (15/41) of the seminal vesicles (10 cases with both prostate and 
seminal vesicles; 5 cases prostate only; 5 cases seminal vesicles only). In women who underwent 
radical cystectomy and pelvic exenteration, 25% (2/8) had involvement of the cervix, 25% (2/8) 
of the uterus, 25% (2/8) of the fallopian tube, 13% (1/8) of the ovary, and 13% (1/8) of the 
vagina. Among radical cystectomies, 6% (3/50) had involvement of the rectum and 2% (1/50) of 
the skeletal muscle of the abdominal wall. One patient who underwent ureterectomy had 
involvement of the spermatic cord (spermatic cord was biopsied during surgery). 
 
3.4 Immunohistochemical stains 
 
For this study, 14 immunohistochemical markers were performed on 26 cases (Table 3). Two 
additional stains, CD138 and e-cadherin, were performed on 48 cases. Among urothelial origin 
markers, GATA3 was the most sensitive (96%, 25/26), followed by p63 (62%, 16/26), uroplakin 
III (46%), and thrombomodulin (19%, 5/19). Keratin 7 (85%, 22/26) and keratin 20 (77%, 20/26) 
were positive in most cases. Breast carcinoma markers were usually negative; PR stained 1 case 
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(intensity 1, proportion 1), while mammaglobin and ER were negative in all cases. 
Neuroendocrine markers CD56 and TTF-1 were each positive in 1 case (intensity 1, proportions 
1 and 2 respectively). Gastrointestinal adenocarcinoma marker CDX2 showed nuclear positivity 
in 4 cases, while nuclear β-catenin staining was absent in all cases. Nuclear p53 staining was 
present in 96% (25/26) of cases. CD138 was positive in 83% (40/48) and e-cadherin was positive 
in 44% (21/48) of cases. 
 
 
Notably, cases with associated exuberant desmoplasia were more likely to have retained 
expression of e-cadherin (68%, 13/19) (Fig. 2). In contrast, e-cadherin expression was retained 
only in a minority of classic (36%, 5/14) and pleomorphic (20%, 3/15) cases. Otherwise, 
differential staining between the morphologic categories was not noted. CD138 was positive in 
most cases (classic 10/14, desmoplastic 18/19, pleomorphic 12/15). Similarly, p63 was positive 
in most cases (classic 3/9, desmoplastic 7/8, pleomorphic 6/9). 
 
3.5 Molecular 
 
UroVysion FISH detected polysomy of chromosomes 3 (13%, 2/15), 7 (20%, 3/15), and 17 
(20%, 3/15) and deletion of chromosome 9p21 (60%, 9/15). FGFR3 mutations were detected by 
PCR in 60% (9/15) of cases (exon 7 in 6 cases, exon 10 in 6 cases, and exon 15 in 8 cases). 
 
3.6 Clinicopathologic results 
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A total of 69 patients were diagnosed with plasmacytoid urothelial cancer. Five patients 
presented with metastatic disease, whereas 64 patients were diagnosed with presumed clinically 
localized plasmacytoid urothelial bladder cancer. Among patients with locoregional disease, 58 
underwent radical cystectomy and the remainder elected for bladder preservation approaches. At 
the time of cystectomy, 6 patients were found to have pathologically organ-confined disease 
(≤pT2 N0), and 51 were diagnosed with non-organ-confined disease (pT3,T4 or N+), 2 of which 
were noted to have diffuse peritoneal carcinomatosis. Twenty-eight (40.5%) patients had positive 
surgical margins, most of which had extensive infiltrative disease not amenable to complete 
excision.  
 
Neoadjuvant chemotherapy appeared to have little effect on this cohort. Of the 14 patients who 
received neoadjuvant cisplatin-based chemotherapy, 10 patients (71.4%) had lymph node 
involvement and 12 (85.7%) had pT3/4 disease at cystectomy. Only one patient was found to 
have a pathologic complete response with pT0N0. Thirteen patients received adjuvant 
chemotherapy, 2 of which received neoadjuvant chemotherapy as well. 
 
Median survival for all patients with plasmacytoid urothelial cancer from the time of initial 
diagnosis was 18 months (IQR 8-78 months) (Fig. 3A), and 14 (IQR 5-74) months from the time 
of cystectomy for patients undergoing radical cystectomy. Of note, there appeared to be three 
morphologic subtypes of plasmacytoid disease; classic, desmoplastic and pleomorphic, with 
distinct survival outcomes (p=0.083). Patients with desmoplastic disease tended to have the 
worst clinical outcomes (median survival 10 months), whereas pleomorphic and classic subtypes 
had somewhat better survival outcomes (Fig. 3B). 
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4. Discussion 
 
The plasmacytoid/diffuse variant is included with a number of variants with established 
prognostic or potential clinical significance outlined in the latest edition of the WHO 
Classification of Tumours of the Urinary System and Male Genital Organs [1]. The WHO, 
International Consultation on Urologic Disease (ICUD), European Association of Urology 
(EAU), American Joint Committee on Cancer (AJCC), and the College of American Pathologists 
(CAP) have all recommended documenting the presence of divergent differentiation/variant 
morphology in pathology reports [1,27,28,29]. However, the difficulty of detecting the 
plasmacytoid variant both in community practices and large academic medical centers is well 
described in the literature [30,31]. With this in mind, we report the clinicopathologic features of 
a large, single-institution case series of urothelial carcinoma with plasmacytoid/diffuse 
differentiation. 
 
A spectrum of morphologic features exists in these cases, a finding which has been suggested but 
not extensively explored in the literature. After reviewing all of the cases for this study, three 
main morphologic groups emerged: (1) classic (29% of cases); (2) desmoplastic (35% of cases); 
and (3) pleomorphic (36% of cases). Some authors have previously applied the term “rhabdoid” 
to cases with marked pleomorphism [22,23,24,25,32].  Notably, a total of 6 cases in our series 
were noted to have marked/bizarre nuclear atypia, but we considered these changes to be within 
the spectrum of plasmacytoid differentiation (3 placed in the desmoplastic category, 3 in the 
pleomorphic category).  
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We applied an extensive immunohistochemical panel to a large number of cases processed in the 
same laboratory. Caution should be exercised when utilizing immunohistochemistry to determine 
whether or not the tumor is urothelial in origin, since some stains such as PR for breast 
carcinoma (1 case; intensity 1 and proportion 1) and CDX2 for gastrointestinal carcinoma (4 
cases; intensity 1-2 and proportion 1-2) can occasionally be positive in the plasmacytoid variant. 
Staining for ER, mammaglobin, and nuclear β-catenin were notably absent in all cases. Finally, 
all tested urothelial origin markers were positive, with GATA3 (96%) being the most frequent. A 
recent study showed similar findings to ours (occasional positive CDX2 and PR), and in addition 
they report staining for GCDFP-15 (24%, 11/45 cases positive) and p-CEA (49%, 22/45 cases) 
[33].  
 
Loss of e-cadherin and positive staining for CD138 have been touted as useful findings 
suggestive of plasmacytoid urothelial carcinoma. However, a recent study calls into question the 
utility of CD138 staining given that positivity in benign urothelium and a variety of benign and 
malignant urothelial tumors was found [34]. We observed a loss of e-cadherin in the majority of 
cases (57%) and CD138 positivity in 83% of cases. Notably, cases with associated exuberant 
desmoplasia were more likely to have retained expression of e-cadherin (68%, 13/19). In 
contrast, e-cadherin expression was retained only in a minority of classic (36%, 5/14) and 
pleomorphic (20%, 3/15) cases. Otherwise, differential staining between the morphologic 
categories was not noted.  
 
The median overall survival for the entire cohort was 21 months. Subsequent analysis of overall 
survival for each morphologic category showed that there was a statistically significant 
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difference between the groups. Cases within the desmoplastic category had the worst overall 
survival (median 12 months). Notably, 88% (22/25) of cases within the desmoplastic category 
were high stage (pT3 or pT4) in comparison to 48% (10/21) of cases in the classic category and 
54% (14/26) of cases in the pleomorphic category. While conclusions are difficult to draw given 
that the number of cases in each category is small, this raises the question of whether cases with 
desmoplasia inherently have a worse outcome or if they have a similar prognosis when matched 
stage for stage with the other groups. The association of worse outcome with certain 
morphologic features has been alluded to in a prior study by Jimenez et al. The authors identified 
3 architectural patterns (nodular, trabecular, infiltrative) within the invasive component of 
urothelial carcinoma and found that cases with any amount of an infiltrative pattern (narrow 
cords or single cells, desmoplasia, necrosis) had a worse outcome (median survival 29 months 
versus 85 months for cases without the infiltrative pattern) [26]. While their findings did not 
reach statistical significance, they do offer further support that the presence of desmoplasia in 
urothelial carcinoma could suggest a worse prognosis.  
 
The molecular aberrations that give rise to urothelial carcinoma with plasmacytoid 
differentiation are still largely unknown. One study that used UroVysion FISH found a 
homozygous deletion of chromosome 9p21 in 15% of cases and a relative deletion in 70% of 
cases, therefore the authors suggested that chromosome 9 may play an important role in the 
pathogenesis of this variant [8]. We performed UroVysion FISH on 15 cases and found 
chromosome 9 to be most commonly aberrant, with a deletion of chromosome 9p21 in 60% of 
cases. A prior study using mutation analysis via capillary electrophoresis did not show any 
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mutations of FGFR3, however we detected FGFR3 mutations in 60% of cases [8]. The 
significance of these findings needs to be further elucidated in future studies. 
 
In conclusion, it is important for the practicing pathologist to be aware of the range of 
morphologic features of the plasmacytoid variant and to be aware of the pitfalls related to 
immunohistochemical staining. Finally, further studies regarding the association between 
desmoplasia and outcome as well as the molecular aberrations leading to the plasmacytoid 
variant are warranted.  
 
 
 
 
 
 
 
 
 
 
 
 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
 
 
20 
References  
 
[1] Moch H, Humphrey, PA, Ulbright, TM, Reuter, VE. World health organization 
classification of tumours of the urinary system and male genital organs. Lyon: 
International Agency for Research on Cancer, 2016. 
[2] Monn MF, Kaimakliotis HZ, Pedrosa JA, et al. Contemporary bladder cancer: Variant 
histology may be a significant driver of disease. Urol Oncol 2015;33:18.e15-20. 
[3] Kaimakliotis HZ, Monn MF, Cheng L, et al. Plasmacytoid bladder cancer: Variant 
histology with aggressive behavior and a new mode of invasion along fascial planes. 
Urology 2014;83:1112-6. 
[4] Rice KR, Koch MO, Kao CS, et al. Lymph node metastases in patients with urothelial 
carcinoma variants: Influence of the specific variant on nodal histology. Urol Oncol 
2015;33:20.e23-9. 
[5] Saphir O. Signet-ring cell carcinoma of the urinary bladder. Am J Pathol 1955;31:223-31. 
[6] Grignon DJ, Ro JY, Ayala AG, et al. Primary signet-ring cell carcinoma of the urinary 
bladder. Am J Clin Pathol 1991;95:13-20. 
[7] Fritsche HM, Burger M, Denzinger S, et al. Plasmacytoid urothelial carcinoma of the 
bladder: Histological and clinical features of 5 cases. J Urol 2008;180:1923-7. 
[8] Keck B, Stoehr R, Wach S, et al. The plasmacytoid carcinoma of the bladder--rare variant 
of aggressive urothelial carcinoma. Int J Cancer 2011;129:346-54. 
[9] Kim B, Kim G, Song B, et al. Her2 protein overexpression and gene amplification in 
plasmacytoid urothelial carcinoma of the urinary bladder. Dis Markers 
2016;2016:8463731. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
 
 
21 
[10] Liang Y, Heitzman J, Kamat AM, et al. Differential expression of gata-3 in urothelial 
carcinoma variants. Hum Pathol 2014;45:1466-72. 
[11] Lim MG, Adsay NV, Grignon DJ, et al. E-cadherin expression in plasmacytoid, signet 
ring cell and micropapillary variants of urothelial carcinoma: Comparison with usual-type 
high-grade urothelial carcinoma. Mod Pathol 2011;24:241-7. 
[12] Lopez-Beltran A, Requena MJ, Montironi R, et al. Plasmacytoid urothelial carcinoma of 
the bladder. Hum Pathol 2009;40:1023-8. 
[13] Nigwekar P, Tamboli P, Amin MB, et al. Plasmacytoid urothelial carcinoma: Detailed 
analysis of morphology with clinicopathologic correlation in 17 cases. Am J Surg Pathol 
2009;33:417-24. 
[14] Paner GP, Annaiah C, Gulmann C, et al. Immunohistochemical evaluation of novel and 
traditional markers associated with urothelial differentiation in a spectrum of variants of 
urothelial carcinoma of the urinary bladder. Hum Pathol 2014;45:1473-82. 
[15] Raspollini MR, Sardi I, Giunti L, et al. Plasmacytoid urothelial carcinoma of the urinary 
bladder: Clinicopathologic, immunohistochemical, ultrastructural, and molecular analysis 
of a case series. Hum Pathol 2011;42:1149-58. 
[16] Ro JY, Shen SS, Lee HI, et al. Plasmacytoid transitional cell carcinoma of urinary 
bladder: A clinicopathologic study of 9 cases. Am J Surg Pathol 2008;32:752-7. 
[17] Fox MD, Xiao L, Zhang M, et al. Plasmacytoid urothelial carcinoma of the urinary 
bladder: A clinicopathologic and immunohistochemical analysis of 49 cases. Am J Clin 
Pathol 2017;147:500-06. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
 
 
22 
[18] Keck B, Wach S, Kunath F, et al. Nuclear e-cadherin expression is associated with the 
loss of membranous e-cadherin, plasmacytoid differentiation and reduced overall survival 
in urothelial carcinoma of the bladder. Ann Surg Oncol 2013;20:2440-5. 
[19] Shimada K, Nakamura M, Ishida E, et al. Urothelial carcinoma with plasmacytoid 
variants producing both human chorionic gonadotropin and carbohydrate antigen 19-9. 
Urology 2006;68:891.e7-10. 
[20] Mai KT, Park PC, Yazdi HM, et al. Plasmacytoid urothelial carcinoma of the urinary 
bladder report of seven new cases. Eur Urol 2006;50:1111-4. 
[21] Cockerill PA, Cheville JC, Boorjian SA, et al. Outcomes following radical cystectomy 
for plasmacytoid urothelial carcinoma: Defining the need for improved local cancer 
control. Urology 2017;102:143-47. 
[22] Parwani AV, Herawi M, Volmar K, et al. Urothelial carcinoma with rhabdoid features: 
Report of 6 cases. Hum Pathol 2006;37:168-72. 
[23] Inagaki T, Nagata M, Kaneko M, et al. Carcinosarcoma with rhabdoid features of the 
urinary bladder in a 2-year-old girl: Possible histogenesis of stem cell origin. Pathol Int 
2000;50:973-8. 
[24] Duvdevani M, Nass D, Neumann Y, et al. Pure rhabdoid tumor of the bladder. J Urol 
2001;166:2337. 
[25] Harris M, Eyden BP, Joglekar VM. Rhabdoid tumour of the bladder: A histological, 
ultrastructural and immunohistochemical study. Histopathology 1987;11:1083-92. 
[26] Jimenez RE, Gheiler E, Oskanian P, et al. Grading the invasive component of urothelial 
carcinoma of the bladder and its relationship with progression-free survival. Am J Surg 
Pathol 2000;24:980-7. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
 
 
23 
[27] Amin MB, Smith SC, Reuter VE, et al. Update for the practicing pathologist: The 
international consultation on urologic disease-european association of urology 
consultation on bladder cancer. Mod Pathol 2015;28:612-30. 
[28] Bernard H. Bochner DEH, Jason A. Efstathiou, Badrinath Konety, Cheryl T. Lee, James 
M. McKiernan, Elizabeth R. Plimack, Victor E. Reuter, Srikala Sridhar, Raghunandan 
Vikram, Walter M. Stadler. Urinary bladder. In: M.B. Amin, ed. Ajcc cancer staging 
manual: Springer, 2016, p. 757-65. 
[29] Amin MB. Protocol for the examination of specimens from patients with carcinoma of 
the urinary bladder. College of American Pathologists, 2013 
[30] Shah RB, Montgomery JS, Montie JE, et al. Variant (divergent) histologic differentiation 
in urothelial carcinoma is under-recognized in community practice: Impact of mandatory 
central pathology review at a large referral hospital. Urol Oncol 2013;31:1650-5. 
[31] Linder BJ, Boorjian SA, Cheville JC, et al. The impact of histological reclassification 
during pathology re-review--evidence of a will rogers effect in bladder cancer? J Urol 
2013;190:1692-6. 
[32] Perez-Montiel D, Wakely PE, Hes O, et al. High-grade urothelial carcinoma of the renal 
pelvis: Clinicopathologic study of 108 cases with emphasis on unusual morphologic 
variants. Mod Pathol 2006;19:494-503. 
[33] Borhan WM, Cimino-Mathews AM, Montgomery EA, et al. Immunohistochemical 
differentiation of plasmacytoid urothelial carcinoma from secondary carcinoma 
involvement of the bladder. Am J Surg Pathol 2017;41:1570-75. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
 
 
24 
[34] Goto K. Cd138 expression is observed in the urothelial epithelium and in various 
urothelial carcinomas, and cannot be evidence for plasmacytoid urothelial carcinoma. Int 
J Surg Pathol 2016;24:614-9. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
 
 
25 
Figure Legends 
 
Fig. 1. Plasmacytoid urothelial carcinoma: 3 morphologic groups. 
 
A, Three cells types are present, including plasmacytoid (circle), monocytoid (arrow), and signet 
ring (arrowhead) (H&E, X400). B, A solid expansile nest of tumor cells is present beneath the 
luminal surface of the urinary bladder (H&E X100). C, Classic category, small cells with 
discohesive cells and cells arranged in a linear pattern are present (H&E X200). D, Pleomorphic 
category, pleomorphic cells with bizarre atypia bordering on rhabdoid differentiation are present 
(H&E X400). E, Desmoplastic category, an exuberant desmoplastic response is present 
surrounding tumor cells (H&E, X100). F, Pleomorphic cells with marked nuclear atypia with 
eccentric, eosinophilic cytoplasm, bordering on rhabdoid differentiation (H&E X400).  
 
Fig. 2. Immunohistochemical findings. 
 
A-C, Classic category (A, H&E X400), with positive expression of CD138 (B, CD138 X400) 
and loss of e-cadherin (C, e-cadherin X400). D, Desmoplastic category (D, H&E X200), with 
retention of e-cadherin (D inset, e-cadherin X200). E-F, Desmoplastic category (H&E X200), 
with an absence of staining for CD138 (E inset, CD138 X200) and retention of staining for e-
cadherin (F, e-cadherin, X400).   
 
Fig. 3. Overall survival for patients with plasmacytoid urothelial carcinoma.  
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A, Overall survival (OS) for all patients with plasmacytoid urothelial carcinoma (median [IQR] 
OS: 20.99 [8.87-82.79], 69 total patients). B, OS of patients with plasmacytoid urothelial 
carcinoma by morphologic category (p=0.0336; median [IQR] OS classic: 20.63 [10.41-NR], 21 
patients; median [IQR] OS desmoplastic: 11.56 [7.69-22.93], 25 patients; median [IQR] OS 
pleomorphic: 82.79 [17.74-85.55], 23 patients 
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Table 1. Antibodies used in this study 
 
Antibody  Clone  Dilution Company 
β-catenin  14  Prediluted Cell Marque, Rocklin, CA 
CD56   123C3  Prediluted Dako, Santa Clara, CA 
CD138   M115  Prediluted Dako, Santa Clara, CA 
CDX2   DAK-CDX2 Prediluted Dako, Santa Clara, CA 
Keratin 7  OV-TL Prediluted Dako, Santa Clara, CA 
Keratin 20  KS20.8  Prediluted Dako, Santa Clara, CA 
E-cadherin  NCH-38 Prediluted Dako, Santa Clara, CA 
Estrogen receptor EP1  1:50  Dako, Santa Clara, CA 
GATA3  L50-823 Prediluted Biocare Medical, Concord, CA 
Mammaglobin  31A5  Prediluted Cell Marque, Rocklin, CA 
P53   DO-7  Prediluted Dako, Santa Clara, CA 
P63   BC4A4  1:100  Dako, Santa Clara, CA 
Progesterone receptor PgR 636 Prediluted Dako, Santa Clara, CA 
Thrombomodulin 1009  1:100  Dako, Santa Clara, CA 
TTF-1   86763/1 Prediluted Dako, Santa Clara, CA 
Uroplakin  AU-1  1:30  Cell Marque, Rocklin, CA 
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Table 2. Clinicopathologic features of 72 cases of urothelial carcinoma with plasmacytoid 
differentiation 
 
Total patients      69 
Male       56 (81) 
Female      13 (19) 
Age median (Range)     68 years (36-91 years) 
Total cases (n)       72 
Biopsy       5 (7) 
TUR       13 (18) 
Radical cystectomy     50 (69) 
Nephroureterectomy     2 (3) 
Ureteretectomy      2 (3) 
pT category
a
 
pT1       1 (2) 
pT2
b
       1 (2) 
pT2a       2 (4) 
pT2b       4 (7) 
pT3a       7 (13) 
pT3b       13 (24) 
pT4
c
       1 (2) 
pT4a       23 (42) 
pT4b       2 (4) 
pN category
a
 
pN0       14 (26) 
pN1       5 (9) 
pN2       31 (58) 
pN - not applicable     4 (7) 
pM category
a
 
pM1       2 (4) 
pM – not applicable     52 (96) 
Positive ureteral margin (n=54 resections)   5 (9) 
Dysplasia      2 (40) 
Soft tissue invasion     3 (60) 
Positive urethral margin (n=50 cystectomies)   2 (4) 
Urothelial carcinoma in situ    1 (50) 
Soft tissue invasion     1 (50) 
Involvement of adjacent organs (n=50 cystectomies)  26 (52) 
Prostate       15 (58) 
Seminal vesicle      15 (58) 
Both prostate and seminal vesicle  10 (38) 
Prostate only     5 (19) 
Seminal vesicle only    5 (19) 
Vagina        1 (4) 
Cervix       2 (8)  
Uterus       2 (8) 
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Ovary        1 (4) 
Fallopian tube      2 (8) 
Rectum       3 (12) 
Skeletal muscle      1 (4) 
Spermatic Cord     1 
Median % plasmacytoid differentiation (range)  30% (5-100%) 
Other variant morphology present    23 (32) 
Clear cell      1 (4) 
Giant cell      1 (4) 
Glandular      3 (13) 
Micropapillary     3 (13) 
Nested       3 (13) 
Sarcomatoid      7 (31) 
Small cell      1 (4) 
Squamous      4 (18) 
Tumor size median (range)     4.7 cm (0.5 – 14.4 cm) 
Concomitant urothelial carcinoma in situ present  31 (43) 
Lymphvascular space invasion present   40 
 
Abbreviations: TUR, transurethral resection of the urinary bladder. 
a
Pathologic pTNM categories assigned to resection specimens (n=54). 
b
Tumor involved muscularis propria only on initial transurethral resection (not on subsequent 
radical cystectomy), therefore not possible to reliably designated as T4a versus T4b. 
c
Nephroureterectomy, therefore no subcategories of T4 staging in the AJCC 7th edition. 
d
Spermatic cord was biopsied during a ureterectomy and was involved by tumor. 
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Table 3. Immunohistochemical stains performed in this study 
 
Stain   Intensity  Proportion  Negative Positive 
   0    1   2   3   0    1   2   3   4   n (%)  n (%) 
β-catenin (nuclear) 26  0   0   0   26  0   0   0   0  26 (100) 0 (0) 
CD56   25  1   0   0   25  1   0   0   0   25 (96)  
 1 (4) 
CD138    8   15 14  11   8   14  7   9  10   8 (17)  
 40 (83) 
CDX2 (nuclear) 22  3   1   0  22  3   1   0   0   22 (85)  
 4 (15) 
Keratin 7   4    3   8  11    4    7   1   2  12   4 (15)   22 (85) 
Keratin 20   6    4  11  5   6    8   4   4   4   6 (23)   20 (77) 
E-cadherin   27  9  6    6   27 10  3   3   5   27 (56)  
 21 (44) 
Estrogen receptor  26  0  0    0   26  0   0   0   0   26 (100)  0 (0) 
GATA3   1    4  4   17   1    4   3   1  17   1 (4)   25 (96) 
Mammaglobin   26  0  0    0   26  0   0   0   0     26 (100) 
 0 (0) 
P53    1    5  6   14   1    4   5   4  12   1 (4)   25 (96) 
P63    10  1  10  5   10  8   2   2   4   10 (38)  
 16 (62) 
Progesterone receptor 25  1  0    0   25  1   0   0   0   25 (96)  
 1 (4) 
Thrombomodulin  21  2  3    0   21  5   0   0   0   21 (81)  
 5 (19) 
TTF-1    25  0  1    0   25   0  1   0   0   25 (96)  
 1 (4) 
Uroplakin   14  4  7    1   14   7  1   1   3   14 (54)  
 12 (46) 
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 Urothelial carcinoma with plasmacytoid differentiation can be divided into 3 
morphologic categories: (1) classic; (2) pleomorphic; and (3) desmoplastic 
 Cases with plasmacytoid differentiation often present at a high stage, and within our 
dataset cases assigned to the desmoplastic group had a worse outcome 
 Urinary bladder origin immunohistochemical stains are sensitive for detecting the 
plasmacytoid variant 
 Molecular aberrations present in conventional urothelial carcinoma are also present in the 
plasmacytoid variant 
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